But the biopharmaceutical company missed on top-line projections.
Results 1 - 3 of 3 for "BIOMARIN"
But the biopharmaceutical company missed on top-line projections.
Filed under: Analyst reports, Staples Inc (SPLS), Genentech Inc (DNA), Analyst initiationsMOST NOTEWORTHY: Solarfun Power, BioMarin Pharmaceutical and Genentech were today's noteworthy initiations: Jefferies initiated Solarfun Power (NASDAQ:SOLF) with a Buy rating and $18 target. The firm believes the one-third stake purchased by Good Energies and new management hires could generate operational...